Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.2453) per share and revenue of $265.85 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last released its earnings results on Thursday, August 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.01. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The company had revenue of $254.56 million during the quarter, compared to analyst estimates of $254.99 million. During the same period in the prior year, the firm posted ($0.78) EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. On average, analysts expect Tandem Diabetes Care to post ($0.66) EPS for the current fiscal year and $0.09 EPS for the next fiscal year.
Tandem Diabetes Care Stock Performance
NASDAQ TNDM opened at $17.65 on Wednesday. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18. Tandem Diabetes Care has a 12 month low of $12.26 and a 12 month high of $29.65. The company’s 50 day moving average is $17.86 and its two-hundred day moving average is $18.92.
Insiders Place Their Bets
In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the transaction, the director directly owned 24,434 shares in the company, valued at $467,911.10. This represents a 6.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on TNDM shares. Barclays raised shares of Tandem Diabetes Care to a “hold” rating in a research note on Wednesday, October 7th. Canaccord Genuity Group set a $40.00 target price on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Mizuho set a $18.00 target price on shares of Tandem Diabetes Care in a research note on Tuesday, October 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tandem Diabetes Care in a report on Tuesday, September 8th. Finally, UBS Group started coverage on Tandem Diabetes Care in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $27.08.
Get Our Latest Analysis on Tandem Diabetes Care
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.
Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.
Read More
- Five stocks we like better than Tandem Diabetes Care
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
